Needham sees no near-term catalysts for Biogen The brokerage said it sees Leqembi’s sales projection “likely to continue to be a slow grind, rather than see an inflection point” and said it ...

The two companies have been partnered on Samsung Bioepis for the best part of a decade, successfully bringing six biosimilar copies of biologic drugs to regulatory approval, but Biogen now says it ...

Biogen has finalised a $900 million payment to settle a whistleblower lawsuit claiming that it paid kickbacks to US doctors to prescribe its multiple sclerosis drugs. According to a Department of ...

Dr Yacine Hadjiat is global head of Biogen Digital Health Solutions. He sat down with pharmaphorum at Frontiers Health 2022 in Milan to discuss how his group approaches digital innovation around ...

Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...

UCB and Biogen say their first phase 3 trial of their systemic lupus erythematosus (SLE) candidate dapirolizumab pegol was a success, and a second is now expected to start before the end of the year.

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA ...

Biogen has taken up an option on a technology developed by Denali that it thinks could help improve the safety and efficacy of amyloid-targeting drugs for Alzheimer’s disease. The technology ...

After getting a green light from the European Commission, Biogen’s Skyclarys is the first approved medicine for the inherited neurological disease Friedreich’s ataxia (FA) in the EU.

Sage to abandon development of neurological disorder drug after multiple failures November 20, 2024 The European Union's drugs regulator on Thursday recommended approval of Eisai and Biogen's ...

BTK has become something of a hot target in MS research, and Biogen's deal follows Sanofi's $3.7 billion takeover of Principia Biopharma and its drug tolebrutinib, which is already in phase 3 ...

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...